A Post-Authorization Study To Assess Long-Term Safety In Patients With Pompe Disease Treated With Avalglucosidase Alfa
Posted Date: Mar 5, 2025
- Investigator: Hani Kushlaf
- Specialties: Neurology, Neuromuscular Disorders
- Type of Study: Observational/Survey
To collect long term safety data and evaluate the important identified risk of infusion associated reactions including hypersensitivity and anaphylactic reactions and the important potential risk of medication errors in participants treated with Avalglucosidase alfa in both clinic/hospital and/or home settings.
Criteria:
The Participant Must Have A Confirmed Diagnosis Of Pompe Disease And Is Treated With Avalglucosidase Alfa Before Enrollment Or Planning To Start Treatment Upon Enrollment.
Keywords:
Pompe Disease, Avalglucosidase Alfa
For More Information:
Ashley Smith
5135584874
ashley.fisher@uc.edu